<DOC>
	<DOCNO>NCT02205242</DOCNO>
	<brief_summary>A first sub-analysis BACE trial address physical activity level subgroup intervention study portable validated activity monitor .</brief_summary>
	<brief_title>BACE Trial Substudy 1 - PROactive Substudy</brief_title>
	<detailed_description>Physical activity strongly reduce exacerbation failure increase physical activity associate relapse . In addition , physical inactivity know associated cardiovascular metabolic morbidity one strong predictor mortality COPD . Apart potential direct effect intervention treatment failure symptom , positive effect physical activity may offer considerable benefit long run . Randomized patient willing participate sub-study monitor activity validate easy-to-wear portable device ( Dynaport® ) . This activity monitor recently thoroughly validate use COPD Pro-Active consortium use baseline , 3 month 9 month visit . We hypothesize positive medical intervention , difference recovery physical activity appreciate . Patients follow standard protocol also wear activity monitor 7 day post discharge hospital ( investigator discretion ) , day 90 ( end treatment ) day 270 ( end follow-up ) . This device register physical activity 7 day also couple standardized patient-validated questionnaire physical activity need fill day 8 cover recall period 7 ( monitor ) day . Patient give inform consent additional measure related activity sub-study . However , individual patient still opt test ( sub-study ) participate medical intervention study ( main study ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Established diagnosis COPD medical doctor ( base clinical history OR pulmonary function test ) Smoking history least 10 packyears ( 10 packyears define 20 cigarette day 10 year , 10 cigarette day 20 year , etc . ) Current hospitalization potential infectious AECOPD treat standard therapy History least one exacerbation last year ( prior current hospital admission ) systemic steroid and/or antibiotic take ECG admission Mechanical noninvasive ventilation moment randomization ( D1 ) Long QT interval ECG ( QTc &gt; 450msec male &gt; 470msec female ) History lifethreatening arrhythmias Myocardial infarction ( NSTEMI STEMI ) less 6 week start study drug Unstable angina pectoris acute myocardial infarction ( NSTEMI STEMI ) admission Drugs high risk long QT interval torsade de pointes ( amiodarone , flecainide , procainamide , sotalol , droperidol , haldol , citalopram , macrolides ) Documented uncorrected severe hypokalemia ( K+ &lt; 3.0 mmol/L ) hypomagnesemia ( Mg2+ &lt; 0.5 mmol/L ) Chronic systemic steroid ( &gt; 4 mg methylprednisolone /day ≥ 2 month ) Actual use macrolides least 2 week Allergy macrolides Active cancer treatment Life expectancy &lt; 3 month Pregnant breastfeeding subject . Woman childbearing potential must pregnancy test perform negative result must document start treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AECOPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Acute exacerbation</keyword>
	<keyword>Hospitalization</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Macrolides</keyword>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Placebo</keyword>
	<keyword>Physical Activity</keyword>
	<keyword>PRO-Active</keyword>
	<keyword>Activity Monitor</keyword>
</DOC>